Neurofibroma is an indication for drug development with over 9 pipeline drugs currently active. According to GlobalData, preregistered drugs for Neurofibroma have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Neurofibroma compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neurofibroma overview
Neurofibromas are benign (non-cancerous) tumors that grow on nerves in the body. They consist of an overgrowth of nerve tissue along with blood vessels and other types of cells and fibres. Neurofibromas can grow on nerves in the skin (cutaneous neurofibroma), under the skin (subcutaneous neurofibroma), or deeper in the body, including in the abdomen, chest, and spine.
For a complete picture of PTSR and LoA scores for drugs in Neurofibroma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
